	US 12,276,657 B2
	Detection of PAR in the CSF of patients with Parkinson's disease
Ted Dawson, Baltimore, MD (US); Valina Dawson, Baltimore, MD (US); Tae-In Kam, Baltimore, MD (US); Liana Rosenthal, Lutherville, MD (US); and Shaida Andrabi, Birmingham, AL (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US)
Filed by The Johns Hopkins University, Baltimore, MD (US)
Filed on Oct. 26, 2022, as Appl. No. 18/049,773.
Application 18/049,773 is a division of application No. 16/616,748, abandoned, previously published as PCT/US2018/035614, filed on Jun. 1, 2018.
Claims priority of provisional application 62/679,161, filed on Jun. 1, 2018.
Claims priority of provisional application 62/514,316, filed on Jun. 2, 2017.
Prior Publication US 2023/0176041 A1, Jun. 8, 2023
Int. Cl. G01N 33/53 (2006.01)

CPC G01N 33/5308 (2013.01) [G01N 2800/2835 (2013.01); G01N 2800/52 (2013.01)]

10 Claims

1. A method for monitoring disease progression of a patient with Parkinson's disease (PD) comprising:

a) measuring a first poly (ADP-ribose) (PAR) concentration in a first sample of cerebrospinal fluid (CSF) from a patient;

b) administering to the patient a first medical treatment for PD;

c) subsequent to a) and b), measuring a second PAR concentration in a second sample of CSF from the patient; and

d) continuing administering the first medical treatment for PD to the patient when the second PAR concentration is the same or lower than the first PAR concentration, or administering a second medical treatment for PD to the patient when the second PAR concentration is higher than the first PAR concentration,

wherein an increase in PAR concentration in CSF is indicative of disease progression, and

wherein the first medical and the second medical treatment for PD are selected from the group consisting of surgery, levodopa, dopamine agonists, amantadine, anticholinergics, COMT inhibitors, MAO-B inhibitors and PARP1 inhibitors, thereby monitoring disease progression.